In the Special Report by Massimo Leone, Carlos Vila and Caroline McGown, ‘Influence of trigger factors on the efficacy of almotriptan as early intervention for the treatment of acute migraine in a primary care setting: the START study’, which appeared in the September 2010 issue of Expert Review of Neurotherapeutics (10[9], 1399–1408 [2010]), it has been brought to our attention that the following inaccuracies appeared in the article:
In the original published article, the following sentences appeared:
Page 1401: “A further two patients did not have adequate data available to assess efficacy and were excluded from the ITT analysis (n = 454, 1147 attacks).”
Page 1402: “The most common type of migraine attack trigger during the study period was stress (37% of patients with triggers and 26% of all study attacks; Table 5).”
Page 1402: “Poor sleep was also a frequently reported study migraine trigger (34% of patients with triggers and 24% of all study subjects).”
These sentences should have read as:
Page 1401: “A further two patients did not have adequate data available to assess efficacy and were excluded from the ITT analysis (n = 454, 1174 attacks).”
Page 1402: “The most common type of migraine attack trigger during the study period was stress (37% of patients with triggers and 25% of all study attacks; Table 5).”
Page 1402: “Poor sleep was also a frequently reported study migraine trigger (34% of patients with triggers and 23% of all study attacks).”
In addition, Table 5 in the article originally appeared as:
Table 5. Types of trigger factors involved in study migraine attacks (n = 1174 attacks).
The correct Table 5 is printed below:
Table 5. Types of trigger factors involved in study migraine attacks (n = 1174 attacks).
The authors and editors of Expert Review of Neurotherapeutics would like to sincerely apologize for any confusion or inconvenience this may have caused.